Telo Genomics Corp (TELO) AI Stock Analysis

• Market Cap: C$5.02M
• Dividend Yield: N/A
• Average Volume (3M): 29.30K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.62
• Revenue Growth: N/A
• EPS Growth: 19.05%
• Country: CA
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): >-0.01
• Shares Outstanding: 100,430,470
• 10 Day Avg. Volume: 22,350
• 30 Day Avg. Volume: 29,304
• PEG Ratio: 0.19
• Price to Book (P/B): 18.74
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: C$0.05 ▲(20.00% Upside)
• Action: Reiterated Date: 03/05/26
• Date: Action: Reiterated 03/05/26

The score is primarily weighed down by weak financial performance (no revenue, ongoing losses and cash burn, and negative equity), which elevates financing and dilution risk. Technicals add a secondary headwind with price trading below major moving averages, while valuation is difficult to support given negative earnings and no dividend yield.

Positive Factors

Proprietary telomere platform

A differentiated single‑chromosome telomere measurement capability is a durable technical advantage in diagnostics and research. It creates a barrier to entry, supports specialized use cases in oncology and aging, and underpins long‑term product relevance across clinical and research markets.

Low absolute debt

Very low reported debt limits interest and refinancing burdens, preserving flexibility for an early‑stage biotech. With minimal interest exposure the company can prioritize R&D or commercialization spending without servicing large debt, reducing short‑term solvency pressure.

Improving cash burn trend

A reduction in TTM operating and free cash flow losses versus the prior year signals better expense control or operational efficiency. While still cash‑negative, an improving burn rate extends runway and lowers immediate financing frequency, aiding longer‑term execution on commercialization plans.

Negative Factors

No revenue

Absence of commercial revenue prevents validation of the business model and means margins are untested. Long‑term value depends on successful product commercialization; without sales, the company remains dependent on external capital and faces execution risk to convert technology into recurring revenue.

Persistent operating losses

Sustained multi‑period net losses erode cash reserves and shareholder equity, increasing the need for financing. Chronic losses raise execution and viability risks for an early‑stage biotech, potentially forcing strategic tradeoffs between R&D, commercial investment, and dilution.

Negative equity / dilution risk

A stockholders' deficit is a structural balance‑sheet weakness that undermines creditor and partner confidence. Negative equity heightens the probability of future equity raises or dilutive financing, which can alter capital structure and impair long‑term shareholder value.

Telo Genomics Corp Business Overview & Revenue Model

Company Description

Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases. The company's lead application is Telo-MM, a solution that provides actionable information to medical professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres. The company serves pathologists, clinicians, academic researchers, and drug developers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada.

How the Company Makes Money

null

Telo Genomics Corp Financial Statement Overview

Summary

Financial statements indicate a high-risk early-stage profile: revenue is consistently zero, losses are persistent (TTM net loss ~2.62M), and cash burn remains significant (TTM operating cash flow ~-1.97M; TTM FCF ~-2.20M). While total debt is low (~161k), the shift to negative equity (stockholders’ deficit ~553k) materially weakens financial flexibility and increases future financing/dilution risk.

Income Statement

The income statement remains very weak: revenue is consistently zero across the annual periods and TTM (Trailing-Twelve-Months), while gross profit is negative, implying the core cost structure is not yet supported by commercial sales. Losses are persistent and sizable (TTM net loss of ~2.62M), with no visible margin improvement because the company is still operating pre/early-revenue. A modest positive is that losses have not meaningfully accelerated versus the last few annual periods, but the absence of revenue makes the path to profitability hard to underwrite from the provided data.

Balance Sheet

Leverage is low in absolute terms (TTM total debt ~161k), but the balance sheet has deteriorated materially as equity has swung to negative in TTM (stockholders’ deficit of ~553k). Total assets are also down sharply versus prior annual snapshots, which reduces financial flexibility. While low debt helps limit interest and refinancing risk, negative equity is a major red flag and raises the likelihood of future dilution or financing needs if operating losses continue.

Cash Flow

Cash generation is weak, with negative operating cash flow in every period and TTM operating cash flow of ~-1.97M, indicating the business is still consuming cash to fund operations. Free cash flow is also consistently negative (TTM ~-2.20M). A relative positive is that TTM cash burn appears somewhat improved versus the most recent annual period (operating and free cash flow losses are smaller than FY2025), but the company remains meaningfully cash-flow negative with ongoing funding requirements.

Breakdown	TTM	Sep 2025	Sep 2023	Jun 2022	Sep 2020	Jun 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-25.57K	-14.45K	-39.54K	-33.11K	-62.23K	-64.72K
EBITDA	-2.57M	-2.69M	-2.67M	-2.78M	-1.01M	-1.15M
Net Income	-2.62M	-2.72M	-2.71M	-2.82M	-1.07M	-1.24M
Balance Sheet
Total Assets	337.79K	911.30K	965.64K	2.93M	3.84M	1.17M
Cash, Cash Equivalents and Short-Term Investments	50.11K	789.29K	796.02K	2.67M	3.64M	920.98K
Total Debt	161.31K	0.00	0.00	32.50K	40.00K	40.00K
Total Liabilities	891.12K	396.32K	375.59K	312.87K	153.66K	393.42K
Stockholders Equity	-553.33K	514.98K	590.06K	2.61M	3.69M	775.25K
Cash Flow
Free Cash Flow	-2.20M	-2.33M	-2.46M	-2.70M	-1.11M	-1.13M
Operating Cash Flow	-1.97M	-2.33M	-2.46M	-2.63M	-1.10M	-1.12M
Investing Cash Flow	-228.24K	-3.25K	-5.12K	-69.06K	-9.31K	-8.67K
Financing Cash Flow	-491.00	2.33M	587.05K	2.68M	3.83M	2.03M

Telo Genomics Corp Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.04
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TELO, the sentiment is Neutral. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.05, and below the 200-day MA of 0.07, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 51.98 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:TELO.

Telo Genomics Corp Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BUX	48 Neutral	C$65.16M	-32.47	―	―	-21.89%	26.36%
AVCR	47 Neutral	C$7.09M	-4.67	-95.29%	―	-59.28%	-1563.64%
TELO	43 Neutral	C$5.02M	-2.38	-9999.00%	―	―	19.05%
SONA	41 Neutral	C$37.74M	-21.43	-434.25%	―	―	10.97%
KNE	41 Neutral	C$6.36M	-3.10	―	―	―	―

Telo Genomics Corp Corporate Events

Telo Genomics Raises $1.39 Million in Final Convertible Debenture Tranche

Telo Genomics Corp. has closed the second and final tranche of its non-brokered private placement of secured convertible debentures, raising $545,000 and bringing total proceeds from the offering to $1,385,000. The debentures carry a 15% annual interest rate, mature on December 15, 2026, and are convertible into common shares at $0.05 per share, with accompanying warrants exercisable at $0.08.

Proceeds from the financing are earmarked for lab trials and general working capital, supporting the company’s ongoing development of telomere-based diagnostic and prognostic tests. The transaction, which includes participation by the company’s CFO and a director under related-party rules, remains subject to TSX Venture Exchange approval and imposes a standard hold period on the new securities under Canadian securities regulations.

The most recent analyst rating on (TSE:TELO) stock is a Hold with a C$0.05 price target. To see the full list of analyst forecasts on Telo Genomics Corp stock, see the TSE:TELO Stock Forecast page.

Telo Genomics Upsizes Convertible Debenture Financing to $1.6 Million

Telo Genomics Corp. has increased its previously announced non-brokered private placement of secured convertible debentures from up to $1.2 million to up to $1.6 million, offering 15% annual interest, conversion at $0.05 per share, and detachable warrants exercisable at $0.08. The company has already raised $840,000 in an initial tranche and plans one or two additional tranches to raise up to $760,000, with net proceeds earmarked for working capital and general corporate purposes, subject to regulatory approvals and standard resale restrictions.

The upsized financing strengthens Telo Genomics’ near-term liquidity as it advances its telomere-based diagnostic platform, including its Multiple Myeloma application, and may help support ongoing product development and commercialization efforts in the competitive liquid biopsy and precision medicine markets. Approval of the offering by the TSX Venture Exchange and successful closing of remaining tranches will be important for funding its operational needs and sustaining momentum in its target oncology and neurological disease segments.

The most recent analyst rating on (TSE:TELO) stock is a Sell with a C$0.05 price target. To see the full list of analyst forecasts on Telo Genomics Corp stock, see the TSE:TELO Stock Forecast page.

Telo Genomics Raises $840,000 in First Tranche of Convertible Debenture Financing

Telo Genomics Corp. has closed the first tranche of a non-brokered private placement of secured convertible debentures, raising gross proceeds of $840,000. The debentures carry 15% annual interest, mature on December 15, 2026, and are convertible into common shares at $0.05 per share, with investors also receiving warrants exercisable at $0.08 per share.

The company plans to use the funds to support lab trials and general working capital, incurring cash finder’s fees and issuing additional finder’s warrants as part of the financing. The offering remains subject to TSX Venture Exchange approval, and all securities issued in this first tranche are subject to a four-month-plus-one-day hold period under Canadian securities laws.

The most recent analyst rating on (TSE:TELO) stock is a Sell with a C$0.04 price target. To see the full list of analyst forecasts on Telo Genomics Corp stock, see the TSE:TELO Stock Forecast page.

Telo Genomics Strengthens Finance Team With Appointment of Veteran CFO John Price

Telo Genomics Corp. has appointed John Price as its new Chief Financial Officer, effective January 30, 2026, bringing more than 30 years of experience in accounting operations, financial planning, M&A and capital markets, including executive roles at several public companies and finance positions in high-growth Silicon Valley technology firms. Price’s arrival, succeeding outgoing CFO Christopher Ross, signals a strengthening of Telo Genomics’ financial leadership as the company advances its telomere-based liquid biopsy and prognostic platforms, potentially enhancing its ability to navigate capital markets, support commercialization of its lead multiple myeloma application and bolster its position within the rapidly expanding field of minimally invasive diagnostics.

The most recent analyst rating on (TSE:TELO) stock is a Hold with a C$0.04 price target. To see the full list of analyst forecasts on Telo Genomics Corp stock, see the TSE:TELO Stock Forecast page.

Telo Genomics Seeks Up to $1.2 Million via Convertible Debenture Financing

Telo Genomics Corp. has launched a non-brokered private placement of secured convertible debentures to raise up to $1.2 million, offering 15% annual interest with a nine-month term and a conversion price of $0.05 per share, along with detachable warrants exercisable at $0.08 per share. The capital is earmarked for lab trials and general working capital, and the financing structure, which includes a four-month hold period and is contingent on TSX Venture Exchange approval, underscores the company’s need to fund ongoing clinical and product development efforts as it advances its telomere-based diagnostics platform toward broader commercialization.

The most recent analyst rating on (TSE:TELO) stock is a Hold with a C$0.04 price target. To see the full list of analyst forecasts on Telo Genomics Corp stock, see the TSE:TELO Stock Forecast page.

Telo Genomics Expands Multiple Myeloma MRD Validation with University of Athens Study

Telo Genomics has launched a retrospective, blood-based multiple myeloma minimal residual disease study with the University of Athens as part of its 2026 multi-center validation program for its TeloView MRD assay. The trial will leverage well-characterized patient blood samples with several years of follow-up and existing next-generation flow MRD data from both blood and bone marrow to compare prognostic performance and relapse prediction, with Telo’s assay targeting greater sensitivity and additional insight through analysis of 3D genomic architecture. This initiative, alongside ongoing prospective trials with Cleveland Clinic and Jewish General Hospital and planned additional retrospective collaborations, is intended to build a robust clinical evidence base that could support broader clinical adoption of Telo’s blood-based MRD technology and strengthen its position in the rapidly expanding global MRD testing market for multiple myeloma.